¿´Æ¬ÊÓƵ

Object moved to here.

¿´Æ¬ÊÓƵ :: Pilot & Feasibility Program Application

¿´Æ¬ÊÓƵ


Metabolic biosensor zebrafish transgenics
Summary Data Summary
Applicant Drummond, Iain
E-Mail Address idrummond@mgh.harvard.edu
Project Title Metabolic biosensor zebrafish transgenics
CBU ID 16GRU3668
External SubContract ID 30835-19
Diabetic Complication Nephropathy
Funding Program Group Pilot & Feasibility [PF2016]
Abstract Hyperglycemic conditions in diabetic patients cause impaired cellular metabolism
in many organs, leading to pathogenesis of complications including Diabetic
Nephropathy (DN). Exact disease etiology, however, remains largely unknown due
to lack of model systems that allow studies of cellular metabolic changes in
vivo. Traditional biochemical measurements are invasive and thus do not always
reflect in vivo conditions. Also, it is difficult to extrapolate data from in
vitro cell culture systems since many cells change their metabolism when
isolated from their native states. A rapidly growing number of
genetically-encoded biosensors have been developed for live monitoring of
cellular metabolites. These biosensors have so far been mainly characterized in
in vitro systems and a relatively few studies have exploited them to visualize
metabolic parameters in vivo. Here, taking advantage of the optical clarity of
embryos combined with the ease of transgenesis, we propose using the zebrafish
as an ideal system for intravital biosensor imaging. In this project, we will
develop versatile transgenic zebrafish incorporating genetically-encoded
fluorescent biosensors for critical metabolites in order to establish an in vivo
imaging platform to investigate metabolism in vivo. We will generate and
distribute transgenic zebrafish designed for tissue and cell-type specific
expression (UAS-GAL4 system) of fluorescent biosensors for ATP/ADP ratio,
intracellular and extracellular glucose, NADH/NAD ratio and other metabolites.
Initial validation of these transgenic lines will be performed by analyzing
changes in biosensor readouts in genetic mutants and/or under conditions of
dysregulated metabolism associated with DN. Successful completion of this Pilot
and Feasibility project will yield new, versatile transgenic models for linking
in vivo physiology and energy status with interventions designed to ameliorate
diabetes pathology.
Application PDF Application Research Plan
Status Contract Executed
Key Personnel
Salary Total Costs 67849
Supply Total Costs 10000
Equipment Total Costs 0
Travel/Other Total Costs 6640
Direct Costs 84489
Indirect Costs Proposed 12673
Total Costs Proposed 97162
Total Costs Approved 48582
Start Date 10/1/2016
End Date 9/30/2017
IFO Name Jones, Martha
IFO E-Mail Address mjones17@partners.org
IACUC/IRB No. 99999
IACUC/IRB Institution Massachusetts General Hospital
Entity ID No. 07-313-0411
Report Request Date 10/30/2017
T1D NO
TypeCount
Invoices 7
Progress Reports 1
Data Submission


Invoices
UrlCBU IDExternal IDInstitutionDateDirectIndirectInvoiceBalancePDF
  View  16GRU366830835-19Massachusetts General Hospital9/22/2017$3,855.64$578.34$4,433.98$242.17View PDF
  View  16GRU366830835-19Massachusetts General Hospital9/22/2017$328.91$49.33$378.24$242.17View PDF
  View  16GRU366830835-19Massachusetts General Hospital7/14/2017$4,215.96$632.38$4,848.34$242.17View PDF
  View  16GRU366830835-19Massachusetts General Hospital6/14/2017$5,549.92$832.50$6,382.42$242.17View PDF
  View  16GRU366830835-19Massachusetts General Hospital5/9/2017$14,810.03$2,221.52$17,031.55$242.17View PDF
  View  16GRU366830835-19Massachusetts General Hospital4/11/2017$154.17$23.13$177.30$242.17View PDF
  View  16GRU366830835-19Massachusetts General Hospital11/15/2017$13,120.00$1,968.00$15,088.00$242.17View PDF


Reports
Click here to cancel and return to funding program application

*Author:
*SubContract:
*Select File:

Click browse and select the file to upload.
(Please upload ONLY TXT, Image Files (not histolgy), PDF, XLS, XLSX, DOC, or DOCX files.)